Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886927 | 0.81 | THRB (0.60) | JAK2THRBKDM4EALDH1A1KDM4A | |
| SCHEMBL9943788 | 0.77 | JAK2 (0.55) | JAK2THRBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL44527 | 0.75 | JAK2 (1.00) | JAK2THRBALDH1A1DHODH | |
| SCHEMBL9715507 | 0.75 | JAK2 (1.00) | JAK2THRBALDH1A1DHODH | |
| SCHEMBL10627886 | 0.74 | JAK2 (0.96) | JAK2THRBALDH1A1DHODH | |
| SCHEMBL10629768 | 0.74 | JAK2 (0.96) | JAK2THRBALDH1A1DHODH | |
| SCHEMBL17930149 | 0.74 | JAK2 (0.67) | JAK2THRBALDH1A1SMN1; SMN2TDP1 | |
| Water SCHEMBL147605 | 0.74 | JAK2 (0.96) | JAK2THRBALDH1A1DHODH | |
| Lithium Ion SCHEMBL10629765 | 0.72 | JAK2 (0.64) | JAK2THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL10627877 | 0.72 | JAK2 (0.64) | JAK2THRBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334306-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120065230-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065230-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | NOX1, NQO1, TXNRD2 | JAK2 1798/4885THRB 4645/4885KDM4E 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.